Company Description
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine.
It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease.
In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems.
The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025.
VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Contact Details
Address: 11555 Sorrento Valley Road, Suite 100 San Diego, California 92121 United States | |
| Phone | 858 224 1000 |
| Website | vivosim.ai |
Stock Details
| Ticker Symbol | VIVS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001497253 |
| CUSIP Number | 68620A302 |
| ISIN Number | US68620A3023 |
| Employer ID | 27-1488943 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Keith E. Murphy | Executive Chairman and Corporate Secretary |
| Norman Staskey | President, Chief Financial Officer and Principal Financial Officer |
| Dr. Amar A. Sethi M.D., Ph.D. | Chief Scientific Officer |
| Tony Lialin | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | PRER14A | Filing |
| Aug 12, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | EFFECT | Notice of Effectiveness |
| Aug 10, 2026 | PRE 14A | Other preliminary proxy statements |
| Aug 6, 2026 | 8-K | Current Report |
| Jul 31, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 30, 2026 | 8-K | Current Report |
| Jul 24, 2026 | 8-K | Current Report |
| Jul 17, 2026 | 8-K | Current Report |
| Jul 14, 2026 | 10-K | Annual Report |